We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Non-Invasive Biosensor Facilitates Early Kidney Disease Detection

By LabMedica International staff writers
Posted on 07 Nov 2024

Traditionally, kidney function has been assessed by measuring blood creatinine levels, which reflect muscle breakdown. More...

Elevated creatinine levels may indicate that the kidneys are not effectively filtering waste. However, these levels can be influenced by an individual's muscle mass and typically rise significantly only after more than 75% of kidney function has been compromised. In contrast, symmetric dimethylarginine (SDMA), a byproduct of protein metabolism, has emerged as a more reliable marker of kidney health. SDMA builds up in the bloodstream because it is not metabolized and is primarily excreted by the kidneys. Measuring SDMA in urine offers a more precise assessment of kidney function. Unlike creatinine, SDMA levels can increase with mild kidney impairment (25–40% loss) and are not significantly affected by muscle mass. Now, a new biosensor utilizing affinity peptides has been developed to accurately measure SDMA levels in urine, providing a practical and cost-effective solution for early diagnosis and monitoring of kidney disease.

The biosensor created by researchers at Chung Ang University (Seoul, Republic of Korea) detects SDMA levels in urine, offering a non-invasive alternative to blood tests, which allows for earlier detection and management of kidney disease. At the core of this biosensor are small, linear peptides that specifically bind to SDMA. These peptides were synthesized and attached to a Ni-Cr layered double hydroxide with graphene oxide (NCL-GO) nanostructure, which is integrated onto gold (Au) electrodes. The sensor was designed using a drop-cast method, where the gold electrodes were coated with a solution containing NCL-GO and left to dry, resulting in a stable coating of peptide-functionalized electrodes (termed peptide/NCL-GO/Au).

The unique two-dimensional structure of NCL-GO consists of interconnected Ni-Cr layered double hydroxide nanosheets and conductive graphene oxide nanosheets. This configuration creates porous, well-connected networks that enhance charge transfer and molecular diffusion, thereby improving the conductivity and surface area of the electrodes. This design amplifies the interaction between the peptides and SDMA, enhancing the sensor's detection capabilities. While other SDMA detection methods, such as chromatography, provide higher sensitivity, this new electrochemical biosensor is user-friendly and does not necessitate sophisticated equipment. As a result, it is more affordable and practical for various environments, including small clinics, remote areas, and resource-limited settings. According to the study published in the journal Biosensors and Bioelectronics, the biosensor features a simple design and delivers rapid results, making it a suitable option for routine health assessments and monitoring.

“Since kidney disease is often diagnosed very late, we aim to develop a sensing tool that patients or clinicians can use to easily monitor kidney health for effective treatment, enabling timely interventions and potential for long-term outcomes,” said Professor Jong Pil Park from Chung-Ang University who led the research team. “The sensor could facilitate earlier diagnosis, advanced monitoring of kidney function, and improved treatment outcomes for millions of patients worldwide. Moreover, our platform technology has the potential to be adapted for detecting other biomarkers, making it a versatile tool applicable across various areas of healthcare.”


New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
C-Reactive Protein Rapid Test
Afinion CRP
New
Glucose Tolerance Test
NERL Trutol
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.